DABRAFENIB PLUS TRAMETINIB IN METASTATIC MELANOMA.
This is a 5-year follow-up for the COMBI trials, which treated patients with unresectable or metastatic melanoma with dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor). Interim analyses have been published and all have shown significant overall and progression-free survivals. This study provides a critical follow-up point for combination BRAFi + MEKi, although the main […]
DABRAFENIB PLUS TRAMETINIB IN METASTATIC MELANOMA. Read More »
